Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment

WU Meng-rui, TANG Mu-ya, ZHENG Bo-hao, ZHOU Sheng-tao

Abstract

In recent years, immunotherapy, as an emerging anti-tumor therapy, has shown great potential in the treatment of both solid and hematologic tumors. There is increasing preclinical and clinical evidence linking the composition of gut microbiome with the efficacy as well as adverse effects of immune checkpoint inhibitor anti-tumor therapy. We summarized in this review the modulatory role of the gut microbiome in antitumor therapy with different immune checkpoint inhibitors. We also discussed the limitations of existing research and prospective development of the further clinical strategies.

 

 Keywords: Gut microbiome, Cancer immunotherapy, Immune checkpoint inhibitors

 

Full Text:

PDF


References


VASAN N， BASELGA J， HYMAN D M. A view on drug resistance in cancer. Nature，2019，575(7782): 299–309.

COUZIN-FRANKEL J. Breakthrough of the year 2013. Cancer Immunother Sci，2013，342(6165): 1432–1433.

FINCK A， GILL S I， JUNE C H. Cancer immunotherapy comes of age and looks for maturity. Nature Commun，2020，11(1): 1–4.

TOPALIAN S L， DRAKE C G， PARDOLL D M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell，2015，27(4): 450–461.

O'DONNELL J S， LONG G V， SCOLYER R A， et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev，2017，52: 71–81.

SENDER R， FUCHS S， MILO R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol，2016，14(8): e1002533[2021-06-14]. https://doi.org/10.1371/journal.pbio.1002533.

OH J， BYRD A L， PARK M， et al. Temporal stability of the human skin microbiome. Cell，2016，165(4): 854–866.

DZUTSEV A， BADGER J H， PEREZ-CHANONA E， et al. Microbes and cancer. Annu Rev Immunol，2017，35: 199–228.

ZITVOGEL L， GALLUZZI L， VIAUD S， et al. Cancer and the gut microbiota: An unexpected link. Sci Transl Med，2015，7(271): 271ps1[2021-06-14]. https://doi.org/10.1126/scitranslmed.3010473.

ARTHUR J C， PEREZ-CHANONA E， MÜHLBAUER M， et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science，2012，338(6103): 120–123.

YU L X， SCHWABE R F. The gut microbiome and liver cancer: Mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol， 2017，14(9): 527–539.

CHAPUT N， LEPAGE P， COUTZAC C， et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol，2017，28(6): 1368–1379.

MATSON V， FESSLER J， BAO R， et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science，2018，359(6371): 104–108.

GOPALAKRISHNAN V， SPENCER C N， NEZI L， et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science，2018，359(6371): 97–103.

ROUTY B， LE CHATELIER E， DEROSA L， et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science，2018，359(6371): 91–97.

HODI F S， CHESNEY J， PAVLICK A C， et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol，2016，17(11): 1558–1568.

LARKIN J， CHIARION-SILENI V， GONZALEZ R， et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med，2015，373(1): 23–34.

SIVAN A， CORRALES L， HUBERT N， et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science，2015，350(6264): 1084–1089.

JIN Y， DONG H， XIA L， et al. The diversity of gut microbiome is associated with favorable responses to anti–programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol，2019， 14(8): 1378–1389.

KATAYAMA Y， YAMADA T， SHIMAMOTO T， et al. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. Transl Lung Cancer Res，2019，8(6): 847–853.

ZHENG Y， WANG T， TU X， et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer，2019，7(1): 193.

VÉTIZOU M， PITT J M， DAILLÈRE R， et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science，2015，350(6264): 1079–1084.

DEROSA L， ROUTY B， ENOT D， et al. Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Clin Oncol，2017，35(6_suppl): 462.

SALGIA N J， BERGEROT P G， MAIA M C， et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti–PD-1 immune checkpoint inhibitors. Eur Urol，2020，78(4): 498–502.

MAGER L F， BURKHARD R， PETT N， et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science，2020，369(6510): 1481–1489.

CHAO M P， ALIZADEH A A， TANG C， et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell，2010，142(5): 699–713.


Refbacks

  • There are currently no refbacks.